Business Context and Reporting Period
This Form 8-K is a current report filed by American BriVision (Holding) Corporation (also referenced as ABVC Biopharma, Inc. in metadata) on November 29, 2017, regarding events occurring on November 23, 2017. The filing addresses corporate governance changes specifically related to the Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel appointments and contains no financial performance data.
Material Changes
The primary material change reported is the appointment of four new members to the Board of Directors to fill vacancies:
- Tsang Ming Jiang: Technical Director at the Industrial Technology Research Institute; former CIO of the Company. He is the brother of Dr. Tsung-Shann Jiang, who controls approximately 69.3% of the Company through YuanGene Corporation.
- Ming-Fong Wu: Senior physician at Taoyuan Hanqun Orthopedic Clinic.
- Norimi Sakamoto: Executive officer and business development manager for Shogun Maitake Canada Co., Ltd. and CEO of Odaira Corporation Co., Ltd.
- Yen-Hsin Chou: Clerk at Mega Securities Co., Ltd.
Guidance, Outlook, and Risks
The filing does not contain management guidance, financial outlook, or specific risk factors. It explicitly states that there are no compensatory arrangements, family relationships (other than the disclosed Jiang relationship), or reportable transactions between the Company and the new board members. No unusual items or contingencies were reported.
Key Facts for Investor Verification
- Verify the extent of influence held by the Jiang family, given the disclosed 69.3% ownership interest and the appointment of a family member to the Board.
- Confirm the strategic rationale for appointing directors with backgrounds in orthopedics, securities, and cloud computing to a biopharma/holding company.
- Check subsequent filings for any financial updates, as this 8-K contains no financial data.